SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series August inventions list 08/11

20110207926 - Novel dihydrotriazine derivative: a tautomer thereof, or a salt of the compound or tautomer, which is useful as a bactericide/disinfectant. In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl group or the like, R2 represents a hydrogen atom or an optionally substituted alkyl group, or alternatively R1 and R2 may... Agent: Hamari Chemicals, Ltd.

20110207927 - 1,4,2-diazaphospholidine derivatives: The present invention relates to novel 1,4,2-diazaphospholidine derivatives, to a process for preparation thereof and to use as catalysts.... Agent: Bayer Materialscience Ag

20110207930 - Improved production method for adefovir dipivoxil: The present invention relates to an improved method of preparing adefovir dipivoxil of Formula 1. The method of the present invention is characterized by using dimethylsulfoxide as a reaction solvent, and comprises a process of preparing adefovir dipivoxil of Formula 1 by allowing adefovir of Formula 2 to react with... Agent: Cj Cheiljedang Corporation

20110207929 - Process for preparing aminocrotonylamino-substituted quinazoline derivatives: e

20110207928 - Purification method for adefovir dipivoxil:

20110207931 - Preparation of valganciclovir and its salts: The application relates to processes for preparing valganciclovir and pharmaceutically acceptable salts thereof, as well as intermediates for the processes. valganciclovir hydrochloride is represented by Formula II.... Agent:

20110207932 - Process for preparing aminocrotonylamino-substituted quinazoline derivatives: e

20110207933 - Process for the preparation of ziprasidone: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially... Agent: Ranbaxy Laboratories Limited

20110201806 - Methods for forming protected organoboronic acids: Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting... Agent:

20110201807 - 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same: wherein R1 is a C1-6 alkyl group, etc., R2 is a hydrogen atom or a COOR3 group, wherein R3 is a tert-C4-6 alkyl group, a 2,2,2-trichloroethyl group or a benzyl group in which the benzene ring moiety may be optionally substituted by one or two atoms or groups independently selected... Agent:

20110201808 - Novel compound having affinity to amyloid: e

20110201809 - Process for preparing entecavir and its intermediates:

20110201810 - Method for preparing 4-[9-(6-aminopurine)]-2-(s)-hydroxyl-butyric acid methyl ester: The present invention discloses a novel method for preparing and purifying 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester. The preparation started from cheap and easily available L-malic acid, which was transformed to intermediate I after simultaneous protection of the groups of 1-carboxyl and 2-hydroxyl. The intermediate I was selectively reduced to intermediate alcohol... Agent: Shanghai Institute Of Materia Medica, Chinese Acad Emy Of Sciences

20110201811 - Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof: A dihydropyridine (DHP) calcium antagonist compound and its preparation method and medical use are related to preparation methods of compounds of general formulas (I) and (II) as shown below and their pharmaceutical salts and applications for treating cardiovascular diseases, and R1 represents a substituted or unsubstituted heterocyclic, aromatic ring or... Agent:

20110201812 - Process for the manufacture of an indolinone derivative: The present invention relates to a process for the manufacture of a specific indolinone derivative and a pharmaceutically acceptable salt thereof, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and its monoethanesulfonate, to new manufacturing steps and to new intermediates of this process.... Agent: Boehringer Ingelheim International Gmbh

20110196151 - Process for the preparation of efavirenz: The present invention is directed to a process for the preparation of Efavirenz, (4S)-6-chloro-4-(cyclopropy-lethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, of formula (I) comprising reacting the intermediate of formula (II) [0045] as a free base or a salt thereof, with diphosgene (TCMCF, trichlormethylchloroformate) Cl3CO—COCl in an organic solvent or in a biphasic medium comprised of an... Agent:

20110196152 - Organometallic complex, and light-emitting element and light-emitting device using the same: It is an object of the present invention to provide a substance capable of emitting phosphorescence. In addition, it is an object of the present invention to provide a light-emitting element that is excellent in chromaticity. One aspect of the present invention is an organometallic complex having a structure represented... Agent: Semiconductor Energy Laboratory Co., Ltd.

20110196153 - Processes of synthesizing dihydropyridophthalazinone derivatives: Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.... Agent:

20110196154 - Amorphous pemetrexed disodium: Processes for the preparation of amorphous pemetrexed disodium, and removal of residual solvents from amorphous pemetrexed disodium.... Agent: Dr. Reddy's Laboratories, Inc.

20110196155 - Crystalline forms of pemetrexed diacid and processes for the preparation thereof: Provided are crystalline forms of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, pemetrexed diacid, and processes for the preparation thereof.... Agent: Sicor Inc.

20110196156 - Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor: A method for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor such as etravirine is provided Typically, etravirine is synthesized by the steps of a Condensing 2,4,6-trichlorpyrimidine with 3,5-dimethyl-4-hydroxybenzonitrile to obtain compound (V), b Condensing compound (V) with 4-aminobenzonitrile to obtain compound (VI), c Ammonolysis of compound (VI) to get compound... Agent:

20110190489 - Novel tricyclic compounds: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological... Agent: Abbott Laboratories

20110190490 - Oxazolopyrimidines as edg-1 receptor agonists: The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for... Agent: Sanofi-aventis

20110190491 - S-triazole alpha- mercaptoacetanilides as inhibitors of hiv reverse transcriptase: A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.... Agent: Ardea Biosciences, Inc.

20110190492 - Diagnostic probe for conformation disease: The invention provides a probe compound useful for early diagnosis of conformation disease, a composition and a kit comprising it for diagnosis for conformation disease, and a medical composition for treatment and/or prevention of conformation disease.... Agent: Tohoku University

20110190493 - Spiroketal-substituted cyclic ketoenols: e

20110190494 - 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component: wherein R1, R2 and R3 each independently represent a hydrogen atom or a methyl group; X represents a carbon atom or a nitrogen atom; Ar1 represents a substituted or unsubstituted aromatic hydrocarbon group; Ar2 represents an C1-4 alkyl-substituted or unsubstituted aromatic 6-membered heterocyclic group having one or two nitrogen atoms,... Agent: Sagami Chemical Research Center

20110190496 - Fused bicyclic mtor inhibitors: e

20110190495 - N-butyramide, the preparation method and use thereof: Disclosed are N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide (which is represented by formula III), its preparation method, intermediates during preparation procedure, preparation method for such intermediates and a method for preparing vardenafil from the compound. In the method for preparing vardenafil, a chloro-sulfonation reaction carries out in the early stage of the preparation procedure.... Agent: Topharman Shanghai Co., Ltd.

20110190497 - Process for production of 2,5 dioxopyrrolidine 3 carboxylate: The present invention provides a novel intermediate which enable to prepare tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3′-pyrrolidine derivatives such as Ranirestat being promising therapeutic agents for diabetic complications in a short process and in an economically advantageous and safe manner, and a process for preparing the same. That is, the present invention provides a process... Agent:

20110190498 - Stereo-specific hydroxylation: The invention relates to a method for the stereospecific hydroxylation of α-amino-S-carboxylic acid derivatives or α-amino-R-sulfonic acid derivatives to form α-amino-β-hydroxy-S-carboxylic acid- or α-amino-β-hydroxy-R-sulfonic acid compounds, with the hydroxyl and acid groups being trans-configured and making use of microorganisms exhibiting hydroxylase activity in a production medium to which the S-carboxylic-... Agent:

20110190499 - Selective synthesis of functionalized pyrimidines: The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.... Agent: Boehringer Ingelheim International Gmbh